USA |NASDAQ |USD |ADR
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | - | $-0.93 | $-0.74 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | - | - | $1.78M |
Bicycle Therapeutics's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 10 | $-3.07 | $-4.61 | $-0.71 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 1 / 2 | $-2.95 | $-2.97 | $-3.42 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 10 | $19.41M | $7.14M | $67.01M |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | $-0.74 | - | - |
| May 5, 2022 | Mar 2022 | $-0.68 | $-0.93 | -36.76% |
| Mar 1, 2022 | Dec 2021 | $-0.61 | $-0.63 | -3.28% |
| Nov 4, 2021 | Sep 2021 | $-0.63 | $-0.59 | 5.80% |
| Aug 5, 2021 | Jun 2021 | $-0.67 | $-0.74 | -10.78% |
| May 6, 2021 | Mar 2021 | $-0.71 | $-0.73 | -3.18% |
| Mar 11, 2021 | Dec 2020 | $-0.41 | $-0.83 | -101.60% |
| Nov 5, 2020 | Sep 2020 | $-0.53 | $-0.52 | 1.89% |
| Aug 5, 2020 | Jun 2020 | $-0.46 | $-0.67 | -45.02% |
| May 7, 2020 | Mar 2020 | $-0.38 | $-0.63 | -64.36% |
| Mar 10, 2020 | Dec 2019 | $-0.52 | $-0.25 | 51.62% |
| Nov 7, 2019 | Sep 2019 | $-0.70 | $-0.53 | 23.74% |
| Aug 8, 2019 | Jun 2019 | $-0.62 | $-0.66 | -6.45% |
| May 23, 2019 | Mar 2019 | - | $-0.49 | - |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 1, 2022 | Dec 2021 | $-2.79 | $-2.69 | - |
| Mar 11, 2021 | Dec 2020 | $-2.27 | $-2.65 | - |
| Mar 10, 2020 | Dec 2019 | $-2.70 | $-1.93 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Aug 3, 2022 | Jun 2022 | - | - | - |
| May 5, 2022 | Mar 2022 | - | - | - |
| Mar 1, 2022 | Dec 2021 | $4.79M | $3.77M | 0.79% |
| Nov 4, 2021 | Sep 2021 | $4.43M | $4.33M | 0.98% |
| Aug 5, 2021 | Jun 2021 | $2.31M | $1.78M | 0.77% |
| May 6, 2021 | Mar 2021 | $1.81M | $1.81M | 1.00% |
| Mar 11, 2021 | Dec 2020 | $3.99M | $3.85M | 0.96% |
| Nov 5, 2020 | Sep 2020 | $3.06M | $3.84M | 1.26% |
| Aug 5, 2020 | Jun 2020 | $2.36M | $1.57M | 0.67% |
| May 7, 2020 | Mar 2020 | $10.35M | $1.13M | 0.11% |
| Mar 10, 2020 | Dec 2019 | $1.85M | $5.28M | 2.85% |
| Nov 7, 2019 | Sep 2019 | $1.32M | $614.00K | 0.47% |
| Aug 8, 2019 | Jun 2019 | $1.03M | $1.52M | 1.48% |
| May 23, 2019 | Mar 2019 | - | $6.38M | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 1, 2022 | Dec 2021 | $14.13M | $11.70M | -17.22% |
| Mar 11, 2021 | Dec 2020 | $10.62M | $10.39M | -2.17% |
| Mar 10, 2020 | Dec 2019 | $9.99M | $13.80M | 38.15% |
BCYC's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.
The average EPS estimation for Bicycle Therapeutics's next quarterly earnings is $-0.74.
Bicycle Therapeutics's previous earnings date was May 5, 2022 for its fiscal quarter ended Mar 31, 2022.
BCYC's earnings per share (EPS) was $-0.93, missing the consensus analysts forecast of $-0.68 by -36.76%.
The EPS was lower than the previous fiscal quarter (Dec 2021) by 47.62%, and lower than the same period a year before (Mar 2021) by 27.40%.
The company reported a net income of $-27.56B.Free cash flow for the quarter was $-31.16M , compared to $-11.50M last quarter and $-14.33M a year before.
BCYC ended the quarter with $44.10M in total debt, a decrease of -0.53% compared to the previous quarter, and an increase of 32.71% compared to the same quarter a year before.
Bicycle Therapeutics's previous annual earnings date was Mar 1, 2022 for its fiscal year ended Dec 31, 2021.
BCYC's earnings per share (EPS) was $-2.69, beating the consensus analysts forecast of $-2.79 by -3.58% , and lower than the previous year's EPS (Dec 2020) by 1.51%.
Revenues were $11.70M, worse than the forecast of $14.13M by -17.22%, and up by 12.58% from previous year's revenue.
The company reported a net income of $-66.82M.
Bicycle Therapeutics reported a free cash flow of $-16.82M for its fiscal year, compared to $-18.99M a year ago.
The company ended the fiscal year with $44.34M in total debt, an increase of 181.06% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
